Background: Polymer-free amphilimus-eluting stents (PF-AES) represent a novel elution-technology
in-stent restenosis, 2 and lowered the rates of repeat revascularization as compared to bare-metal stents. 3 First-generation DES were, however, associated with delayed coronary vessel wall healing and an increased risk of late stent thrombosis. 4 Post-mortem human autopsies 5, 6 revealed a chronic inflammatory response to permanent polymers and incomplete endothelialization that was associated with the occurrence of late stent thrombosis. It has been postulated that polymer-free DES may overcome the limitation of polymer-induced adverse events, and may further improve clinical outcomes. 7 The polymer-free amphilimus-eluting stent (PF-AES) was designed to evaluate a novel elution strategy in coronary stenting. PF-AES is clearly distinctive from contemporary DES as it has thin cobaltchromium struts that are coated with a de-ionized I-carbon layer to promote rapid endothelialization 8 and a novel elution-technology using laser-cut wells (i.e., abluminal reservoirs). A mixture of longchain fatty acids is combined with sirolimus is found inside these abluminal reservoirs. After implantation of PF-AES, an initial peak concentration is obtained, followed by sustained drug-release in which 50% drug is eluted in the first 18 days, and complete drugelution within 90 days.
Currently, only limited data on the clinical safety and efficacy of this novel elution-technology used in PF-AES are available.
Hence, with this comprehensive analysis we aimed to assess the 1-year clinical outcomes of PF-AES as compared to latest-generation permanent polymer zotarolimus-eluting stents (PP-ZESs) in a realworld all-comers setting.
| METHODS

| Study design
This prospective registry was conducted at our tertiary center. The polymer-free PF-AES (Cre8, coronary stent system, Alvimedica, Istanbul, Turkey) was compared to a widely used latest-generation PP-ZES (Resolute Integrity, Medtronic Vascular, Santa Rosa, USA).
All-comers patients with stable coronary artery disease or acute coronary syndromes, and at least one coronary artery lesion with more than 50% diameter stenosis eligible for treatment with either
PF-AES or PP-ZES implantation between January 2014 and
February 2016 were consecutively enrolled. Exclusion criteria were (1) implantation of bare-metal stents, (2) a combination of DES, or (3) revascularization prior to transcatheter aortic valve implantation. This registry was reported according to the STROBE statement, 9 and conducted according to the principles of the Declaration of Helsinki. Our study was approved by local Ethics Committee and each patient provided informed consent for data collection and subsequent analysis.
| Percutaneous coronary intervention
Coronary lesions were treated according to standard interventional techniques, and radial route of access as the default strategy. Revascularization strategies (e.g., intravascular imaging guidance, atherectomy, direct stenting, and post-dilatation), or the use of Glycoprotein IIb/IIIa inhibitors was left to the operators' discretion. Post-procedural dual antiplatelet therapy (DAPT) was prescribed for 3-6 months in stable coronary artery disease and 12 months in acute coronary syndrome as according to current ESC guidelines. Thereafter, acetylsalicylic acid was continued indefinitely.
| Clinical outcomes and definitions
The primary outcome of the study was major adverse cardiac and cerebrovascular events (MACCE) at 1-year follow-up, defined as a composite of: cardiac death, myocardial infarction, stroke, target-lesion revasculariza- Triple therapy was defined as aspirin, clopidogrel and acenocoumarol. ACE = angiotensin-converting-enzyme, CAD = Coronary Artery Disease, DAPT = Dual Antiplatelet Therapy, NSTEMI = non-ST-segment elevation-myocardial infarction, PCI = Percutaneous Coronary Intervention, PF-AES = Polymer-free amphilimus-eluting stent, PP-ZES = Zotarolimus-eluting Stent, STEMI = ST-segment elevation-myocardial infarction.
| Data acquisition and patient follow-up
Detailed clinical data, procedural data, and angiographic parameters were collected. All patients enrolled were prospectively followed during visits to the out-patient clinics, by a medical questionnaire, and by telephone assessment at 1-year follow-up by a trained research coordinator. Data regarding patient survival status were collected from the Dutch Civil Registry. Angiographic follow-up was performed when clinically indicated.
| Statistical analysis
Categorical variables were reported as frequencies (n) and percentages (%) and compared using the Chi-square or Fisher's exact test as appropriate. Continuous variables were expressed as mean AE standard deviation and compared using Student's t-test when normally distributed, and compared using the Mann-Whitney test when non-parametrical distributed. Time-to-event was evaluated using the Kaplan-Meier method, analyzed using the log-rank test, and reported according to good clinical practice statement. 13 Clinical follow-up was censored at the date of last contact or at 1 year, whichever came first. Missing data, if not exceeding 10%, were imputed using multiple imputation chained equation with 10 imputed datasets with 10 iterations 14 after visual checking the randomness of missing data. A propensity-score (i.e., the probability of a patient being assigned to PF-AES or PP-ZES implantation) was calculated with a non-parsimonious approach using binary logistic regression based on: age, sex, body-mass index, clinical indication, diabetes mellitus, hypertension, dyslipidemia, obstructive pulmonary disease, peripheral artery disease, a history of: acute coronary syndrome, PCI, 
| Procedural characteristics
Lesion and procedural characteristics are summarized in Table 2 .
The left main coronary artery was treated in roughly 6%. The vs. 82.6, P < 0.001).
| Clinical outcomes
One-year adverse clinical events stratified by stent type are summarized in Table 3 . Clinical follow-up at 1 year was available for 726 patients 98.9% (PF-AES 98.7% vs. PP-ZES 99.2%, P = 0.73). The primary outcome of MACCE (Figure 2 ) occurred in 92 patients and was similar in the crude unadjusted analysis for PF-AES as compared to PP-ZES (11.5%
vs. 13.6% respectively). The secondary outcome of TLF occurred in with no significant between-group differences for the primary outcome. Also consistent with our data, another propensity-score matched analysis 21 reported a similar 1-year TLF rate of PF-AES (4.9%) as we found, and compared them to biodegradable polymer biolimus-eluting stents (8.2%, P < 0.001) in patients with and without diabetes mellitus. Importantly, the rate of definite stent thrombosis at 1-year follow-up was low for PF-AES and biolimus-eluting stents. Finally, Polymers that are used in contemporary DES for stabilizing antiinflammatory drugs and sustained drug-release, lose function at the time the drug is fully eluted. Even more important, polymers are associated with hypersensitivity reactions leading to chronic inflammation, delayed and incomplete stent strut endothelialization that may eventually predispose for late or very late stent thrombosis. 27 In fact, the cumulative incidence of definite stent thrombosis in our study was low, despite a relatively short period of DAPT in stable coronary artery disease, supporting that PF-AES are safe. Even though these findings are positive, the lack of polymer in PF-AES cannot rule out late or very late stent thrombosis as this phenomenon can be the result of other triggers (e.g., complex or calcified lesions, stent under expansion, uncovered stent edge dissection, or stent malposition). A FIGURE 3 Propensity-score adjusted cox proportional-hazard regression of one-year clinical outcomes. BARC, Bleeding Academic Research Consortium; CD, cardiac death; CD-TVR, clinically driven target-vessel revascularization; CI, confidence interval; HR, hazard ratio; MACCE major adverse cardiac and cerebrovascular events; MI, myocardial infarction; PF-AES, polymer-free amphilimus-eluting stent; PP-ZES, permanent polymer zotarolimus eluting stent; TLF, targetlesion failure; TLR, target-lesions revascularization FIGURE 4 Subgroup analyses for the primary outcome at 1-year follow-up. CKF, chronic kidney failure; MI, myocardial infarction; PF-AES, polymer-free amphilimus-eluting stent; PP-ZES, permanent polymer zotarolimus-eluting stent previous report 28 investigating patients needing short DAPT (i.e. ≤3 months) showed that PF-AES was safe regarding recurrent ischemic events and was associated with a reduction of major bleeding events related to DAPT. Our data showed low stent-related adverse clinical events in PF-AES as compared to PP-ZES. We speculate that a short duration of DAPT (3 months) following latest-generation DES in stable coronary artery disease may be safe, as we observed relatively low rates of ischemic events.
A growing body of evidence 20, 21, 25, 29, 30 demonstrates that PF-AES performs well in diabetic and non-diabetic patients. These findings may be explained by the distinct features of PF-AES ( numerically lower in PF-AES, we advocate that our data should be confirmed in a large randomized trial to evaluate the safety and efficacy of this polymer-free amphilimus-eluting technology.
| Study limitations
Some limitations of our analysis should be acknowledged. First, the absence of randomization was controlled by a propensity-score adjusted Cox proportional-hazards regression. With this methodology it is not able to correct for unmeasured confounders, and therefore some degree of bias cannot be excluded. We believe, however, that the lack of randomization will not change the overall conclusion of our findings. Second, our comprehensive analysis should be viewed in the scope of the sample size as the number of events were relatively low, and it was not primarily powered to evaluate individual clinical outcomes. Third, long-term clinical outcomes should be evaluated to confirm the safety and efficacy of the novel-elution technology used in PF-AES.
| CONCLUSION
In this prospective registry, PF-AES was associated with promising 1-year clinical outcomes and a safety profile similar to latestgeneration PP-ZES. A randomized trial should aim to evaluate clinical non-inferiority of PF-AES and confirm our data on the clinical safety and efficacy of this novel-eluting technology. FIGURE 5 Principal characteristics of the polymer-free amphilimuseluting stent. The coronary stent platform is made from a thin-strut (80 μm) cobalt-chromium alloy, coated with a passive ultra-thin (<0.3 mm) layer that optimizes hemocompatibility (bio-inducer surface) 32, 33 to accelerate endothelialization. 8, 31 Sustained and homogeneous release of sirolimus (90 pg/cm 2 ) is facilitated according to Fick's law and completed over 90 days by laser-dug wells on the stent surface (abluminal reservoirs) that are filled with a mixture of the drug and long-chained fatty acids (amphilimus formulation). This distinct feature acts as an active drug-carrier to enhance drug-penetration and modulates bioavailability directly into the vessel wall 34 [Color figure can be viewed at wileyonlinelibrary.com]
